

GLAXOSMITHKLINE PLC

Form 6-K

April 17, 2018

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending 17 April 2018

GlaxoSmithKline plc

(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F ☒ Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No ☒

GlaxoSmithKline plc (the 'Company')

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Ms E Walmsley  
b) Position/status Chief Executive Officer

- c) Initial notification/  
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc  
b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- Ordinary shares of 25 pence each ('Ordinary Shares')  
a) Description of the financial instrument ISIN: GB0009252882

- b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 April 2018 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.

Price(s)	Volume(s)
£14.296	248.648
£14.296	248.630
£14.296	270.719
£14.296	270.702
£14.296	947.431

- c) Price(s) and volume(s) £14.296 270.719

- d) Aggregated information

Aggregated volume Price

1,986.129  
£14.296

- e) Date of the transaction 2018-04-12  
f) Place of the transaction London Stock Exchange  
(XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr R G Connor  
b) Position/status President, Global  
Manufacturing & Supply

- c) Initial notification/  
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction  
platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc  
b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of  
instrument; (ii) each type of transaction; (iii) each date; and (iv) each  
place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence  
each ('Ordinary Shares')  
ISIN: GB0009252882

- b) Nature of the transaction Acquisition of Ordinary  
Shares following the  
re-investment of dividends  
paid to shareholders on 12  
April 2018 on Ordinary  
Shares held in the Company's  
Deferred Annual Bonus Plan.

Price(s) Volume(s)  
£14.296 168.936

- c) Price(s) and volume(s) £14.296 140.960

£14.296 140.944

£14.296 200.719

d) Aggregated information

Aggregated volume Price

651.559  
£14.296

e) Date of the transaction 2018-04-12  
 f) Place of the transaction London Stock Exchange  
 (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr L Debruyne  
 b) Position/status President, Global Vaccines  
 c) Initial notification/  
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence  
 each ('Ordinary Shares')  
 ISIN: GB0009252882

b) Nature of the transaction Acquisition of Ordinary  
 Shares following the  
 re-investment of dividends  
 paid to shareholders on 12  
 April 2018 on Ordinary  
 Shares held in the Company's  
 Deferred Annual Bonus Plan.

Price(s)	Volume(s)
£14.296	236.924

c) Price(s) and volume(s) £14.296 236.907

£14.296	300.644
---------	---------

d) Aggregated information  
 Aggregated volume Price

774.475  
 £14.296

e) Date of the transaction 2018-04-12  
 f) Place of the transaction London Stock Exchange  
 (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr S Dingemans

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- b) Position/status Chief Financial Officer
- c) Initial notification/  
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882
- b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 April 2018 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.
- | Price(s) | Volume(s) |
|----------|-----------|
| £14.296  | 328.359   |
| £14.296  | 328.341   |
- c) Price(s) and volume(s)
- |         |         |
|---------|---------|
| £14.296 | 245.940 |
| £14.296 | 245.940 |
| £14.296 | 670.469 |
- d) Aggregated information
- |                   |           |
|-------------------|-----------|
| Aggregated volume | 1,819.049 |
| Price             | £14.296   |
- e) Date of the transaction 2018-04-12
- f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Mr N Hirons
- b) Position/status SVP, Global Ethics & Compliance
- c) Initial notification/  
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc  
b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882

- b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 April 2018 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.

Price(s)	Volume(s)
£14.296	121.408

£14.296	121.408
---------	---------

- c) Price(s) and volume(s) £14.296 89.098

£14.296	89.082
---------	--------

£14.296	105.267
---------	---------

Aggregated information

- d) Aggregated volume Price  
526.263  
£14.296

- e) Date of the transaction 2018-04-12

- f) Place of the transaction London Stock Exchange  
(XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr L Miels  
b) Position/status President, Global Pharmaceuticals

- c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc  
b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

	Ordinary shares of 25 pence each ('Ordinary Shares')				
a) Description of the financial instrument	ISIN: GB0009252882				
b) Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 April 2018 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.				
c) Price(s) and volume(s)	<table border="0"> <tr> <td>Price(s)</td> <td>Volume(s)</td> </tr> <tr> <td>£14.296</td> <td>190.616</td> </tr> </table>	Price(s)	Volume(s)	£14.296	190.616
Price(s)	Volume(s)				
£14.296	190.616				
d) Aggregated information	n/a (single transaction)				
e) Date of the transaction	2018-04-12				
f) Place of the transaction	London Stock Exchange (XLON)				

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Mr B McNamara
b) Position/status	CEO, GSK Consumer Healthcare

c) Initial notification/ amendment	Initial notification
---------------------------------------	----------------------

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

	American Depositary Shares ('ADSs')
a) Description of the financial instrument	ISIN: US37733W1053

b) Nature of the transaction	Acquisition of ADSs following the re-investment of dividends paid to shareholders on 12 April 2018 on ADSs held in the Company's Deferred Annual Bonus Plan.
------------------------------	--

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

	Price(s)	Volume(s)
	\$40.62	102.618
c) Price(s) and volume(s)		
	\$40.62	100.616
Aggregated information		
d)	203.235	
Aggregated volume Price	\$40.62	
e) Date of the transaction	2018-04-12	
f) Place of the transaction	New York Stock Exchange (XNYS)	
1. Details of PDMR/person closely associated with them ('PCA')		
a) Name	Mr D S Redfern	
b) Position/status	Chief Strategy Officer	
c) Initial notification/ amendment	Initial notification	
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a) Name	GlaxoSmithKline plc	
b) LEI	5493000HZTVUYLO1D793	
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882	
b) Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 April 2018 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.	
	Price(s)	Volume(s)
	£14.296	154.513
	£14.296	154.513
c) Price(s) and volume(s)	£14.296	112.131
	£14.296	112.115
	£14.296	194.831

Aggregated information		
d)		
Aggregated volume	Price	
	728.103	
	£14.296	
e)	Date of the transaction	2018-04-12
f)	Place of the transaction	London Stock Exchange (XLON)
1.	Details of PDMR/person closely associated with them ('PCA')	
a)	Name	Ms C Thomas
b)	Position/status	SVP, Human Resources
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted	
	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882	
a)	Description of the financial instrument	
	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 April 2018 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.	
b)	Nature of the transaction	
	Price(s)	Volume(s)
	£14.296	226.048
	£14.296	226.048
c)	Price(s) and volume(s)	
	£14.296	168.773
	£14.296	168.773
	£14.296	211.772
d)	Aggregated information	

Aggregated volume Price

1,001.414  
£14.296

- e) Date of the transaction 2018-04-12  
f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Ms K Terrell  
b) Position/status Chief Digital & Technology Officer

- c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc  
b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument American Depositary Shares ('ADSs')  
ISIN: US37733W1053

- b) Nature of the transaction Acquisition of ADSs following the re-investment of dividends paid to shareholders on 12 April 2018 on ADSs held in the Company's Deferred Annual Bonus Plan.

- c) Price(s) and volume(s) Price(s) Volume(s)  
\$40.62 34.022

Aggregated information

- d) n/a (single transaction)

Aggregated volume Price

- e) Date of the transaction 2018-04-12  
f) Place of the transaction New York Stock Exchange (XNYS)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr P C Thomson  
b) Position/status President, Global Affairs  
c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882	
b) Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 April 2018 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.	
	Price(s)	Volume(s)
	£14.296	138.304
c) Price(s) and volume(s)	£14.296	106.250
	£14.296	131.812
d) Aggregated information		
Aggregated volume Price	376.366	£14.296
e) Date of the transaction	2018-04-12	
f) Place of the transaction	London Stock Exchange (XLON)	

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Mr D E Troy
  - b) Position/status SVP & General Counsel
  - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
  - a) Description of the financial instrument American Depositary Shares ('ADSs')

ISIN: US37733W1053

b) Nature of the transaction	Acquisition of ADSs following the re-investment of dividends paid to shareholders on 12 April 2018 on ADSs held in the Company's Deferred Annual Bonus Plan.	
	Price(s)	Volume(s)
	\$40.62	131.482
c) Price(s) and volume(s)	\$40.62	131.482
	\$40.62	108.898
	\$40.62	108.881
	\$40.62	116.999
d) Aggregated information		
	Aggregated volume Price	597.742 \$40.62
e) Date of the transaction	2018-04-12	
f) Place of the transaction	New York Stock Exchange (XNYS)	

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: April 17, 2018

By: VICTORIA WHYTE

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc